**Sir,**

We appreciate the insightful comments provided by [@bib4] regarding our recent report 'Detection of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer\' ([@bib1]).

According to GenBank data, two amino-acid sequences of the non-tumour-derived Merkel cell polyomavirus (MCPyV) strain Appendix206 (GenBank accession numbers JN038578 and JN038579) are deposited under the same title 'Merkel cell polyomavirus isolate Appendix206 large T antigen gene, partial cds; and small T antigen gene, complete cds\'. In our study ([@bib1]), we compared the sequences of Appendix206 (JN038578) with the sequences of viral strains isolated from our four MCPyV-positive non-small cell lung cancers (NSCLCs) (SCC15, AC35, AC39 and AC43). As [@bib4] noted, the two sequences deposited in GenBank with the same descriptions of 'definition\', 'source of organism\' and 'features\' are confusing and indistinguishable.

Our MCPyV strains had the wild-type retinoblastoma tumour-suppressor protein-binding motif. The more important results in our paper are the detection of integrated and *large T* (*LT*) gene mutated forms of MCPyV in one squamous cell carcinoma (SCC15) and one adenocarcinoma (AC43). The tumour AC43 possessed both an integrated MCPyV and frameshift mutations that truncate the *LT* gene to eliminate its helicase activity. The tumour SCC15 appears to have wild-type MCPyV, as the full-length *LT* gene sequence was determined by direct sequencing of polymerase chain reaction products, as shown in Figure 4 in our previous report ([@bib1]). However, we demonstrated that the AC43 tumour also carried integrated virus with the virus--host junction located in the *LT* gene at nucleotide position 2738, interrupting the helicase domain (nucleotide positions 1947--3017). These findings suggest the coexistence in the tumour of an integrated/truncated form and an episomal form of MCPyV. This phenomenon was also reported in MCPyV-positive Merkel cell carcinoma ([@bib2]; [@bib3]).

Thus, we found two cases of NSCLC infected with MCPyV possessing a tumour-specific feature, which to our knowledge has not been reported in any specific malignancy other than Merkel cell carcinoma and chronic lymphocytic leukaemia. As [@bib4] commented, a follow-up study of these MCPyV-positive NSCLC cases is well worth doing.
